Fibroblast growth factor 21, or FGF21, is a liver-secreted protein that helps the body maintain its energy balance. In animal models of diet-induced obesity, boosting FGF21 levels reliably leads to substantial weight reduction, primarily by ramping up energy expenditure rather than suppressing appetite. Because obesity is a chronic, multi-layered condition that elevates the risk of type 2 diabetes, cardiovascular disease, and certain cancers, understanding exactly how FGF21 works has become a high-stakes scientific endeavor. The latest clues, published in Cell Reports, turn a long-standing hypothesis on its head.
The Hypothalamus Assumption Falls Short
For decades, the hypothalamus has been seen as the master control center for body weight. It regulates hunger, satiety, and metabolic rate, and it contains glutamatergic neurons that carry β-klotho – the essential co-receptor that allows cells to detect FGF21. Naturally, researchers suspected that the hormone’s slimming effects were mediated by this well-known brain region.
To test the idea, the team generated transgenic mice in which β-klotho was deleted specifically in hypothalamic cells. After putting the animals on a high-fat diet to induce obesity, they delivered FGF21 continuously for two weeks using miniature osmotic pumps. The result was striking in its absence: the mice lacking hypothalamic β-klotho lost just as much weight as their normal littermates. In a complementary experiment, animals engineered to express β-klotho only in the hypothalamus failed to shed weight when given the hormone. The message was clear – the hypothalamus is not the primary driver of FGF21-induced weight loss. The real command post had to be somewhere else.
To test the idea, the team generated transgenic mice in which β-klotho was deleted specifically in hypothalamic cells. After putting the animals on a high-fat diet to induce obesity, they delivered FGF21 continuously for two weeks using miniature osmotic pumps. The result was striking in its absence: the mice lacking hypothalamic β-klotho lost just as much weight as their normal littermates. In a complementary experiment, animals engineered to express β-klotho only in the hypothalamus failed to shed weight when given the hormone. The message was clear – the hypothalamus is not the primary driver of FGF21-induced weight loss. The real command post had to be somewhere else.
An Unexpected Signal in the Hindbrain
Attention shifted to the hindbrain, where the same β-klotho-equipped glutamatergic neurons also reside, particularly in the nucleus of the solitary tract and the area postrema – a region famously associated with the vomiting reflex. Intriguingly, these areas are already recognized as critical nodes for metabolic control and are thought to be the targets of glucagon-like peptide-1 (GLP-1) receptor agonists, a widely prescribed class of anti-obesity medications.
When the scientists removed β-klotho from the hindbrains of obese mice, FGF21 treatment no longer produced any meaningful drop in body weight. Conversely, restricting β-klotho expression solely to this part of the brain was sufficient to restore the hormone’s weight-lowering effect. Using a genetic tagging technique that marks activated neurons with the red fluorescent protein tdTomato, the researchers confirmed that FGF21 directly switches on the β-klotho-positive cells in the hindbrain.
“We assumed the signal would go to the hypothalamus, a region famous for body weight control, so we were very surprised to find the signal going to the hindbrain – exactly where GLP-1 analogs are thought to work,” said Professor Matthew Potthoff, the study’s senior author.
When the scientists removed β-klotho from the hindbrains of obese mice, FGF21 treatment no longer produced any meaningful drop in body weight. Conversely, restricting β-klotho expression solely to this part of the brain was sufficient to restore the hormone’s weight-lowering effect. Using a genetic tagging technique that marks activated neurons with the red fluorescent protein tdTomato, the researchers confirmed that FGF21 directly switches on the β-klotho-positive cells in the hindbrain.
“We assumed the signal would go to the hypothalamus, a region famous for body weight control, so we were very surprised to find the signal going to the hindbrain – exactly where GLP-1 analogs are thought to work,” said Professor Matthew Potthoff, the study’s senior author.
Lighting Up Brown Fat and Burning Calories
Earlier work established that FGF21’s primary mechanism is boosting energy expenditure rather than curbing food intake. The new study shows that the hindbrain circuit is essential for this calorie-burning command. When mice with a hindbrain-specific β-klotho knockout were exposed to FGF21, the usual surge in thermogenic gene expression in brown adipose tissue was severely blunted, and their metabolic rate remained stubbornly flat.
Using chemogenetic tools to selectively stimulate the relevant glutamatergic neurons in the nucleus of the solitary tract and area postrema, the team demonstrated that activating this population is necessary for the energy-expenditure response – though not by itself sufficient to raise metabolic rate without FGF21 present.
Using chemogenetic tools to selectively stimulate the relevant glutamatergic neurons in the nucleus of the solitary tract and area postrema, the team demonstrated that activating this population is necessary for the energy-expenditure response – though not by itself sufficient to raise metabolic rate without FGF21 present.
Tracing the Circuit’s Next Stop
To map where these signals travel next, the researchers injected a fluorescently labeled virus that allowed them to trace the projections of the β-klotho-positive neurons. The fibers led predominantly to the parabrachial nucleus, a relay station that integrates visceral signals and modulates feeding and thermoregulation. Targeted chemogenetic activation of this pathway recapitulated the weight-lowering effects driven by FGF21, cementing the parabrachial nucleus as a key downstream hub in the circuit.
A New Perspective for Metabolic Therapies
By pinpointing the nucleus of the solitary tract, area postrema, and their link to the parabrachial nucleus as the primary neural targets of FGF21, the study rewrites the roadmap of metabolic regulation in the brain. It also uncovers a notable overlap with the anatomical substrates of GLP-1-based drugs, suggesting that diverse pharmacological strategies may ultimately converge on a shared set of hindbrain circuits to control body weight. Whether these findings will translate into human biology remains an open question, but they offer a fresh vantage point for developing more precise interventions against obesity – one that directs attention to the back of the brain rather than its deep-seated center.
Publication date: 2026.04.24
Source:
Lin Y. et al. Pharmacological administration of FGF21 reverses obesity through a parabrachial-projecting neuron population in the hindbrain. Cell Rep. 2026 Mar 31;45(4):117093. doi: 10.1016/j.celrep.2026.117093. Epub ahead of print. PMID: 41920739; PMCID: PMC13196181.
https://www.cell.com/cell-reports/fulltext/S2211-1247(26)00171-3
Source:
Lin Y. et al. Pharmacological administration of FGF21 reverses obesity through a parabrachial-projecting neuron population in the hindbrain. Cell Rep. 2026 Mar 31;45(4):117093. doi: 10.1016/j.celrep.2026.117093. Epub ahead of print. PMID: 41920739; PMCID: PMC13196181.
https://www.cell.com/cell-reports/fulltext/S2211-1247(26)00171-3